All In Biotech

Drug Trial Radar · NCT03616587

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)

Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

396

Actual

Start

Oct 11, 2018

Primary completion

Sep 16, 2024

Study completion Jun 24, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER Positive, HER2 Negative Advanced Breast Cancer (SERENA-1)

Conditions

  • ER+ HER2- Advanced Breast Cancer

Interventions

  • AZD9833Drug

    Part A: AZD9833 monotherapy dose escalation.

  • AZD9833Drug

    Part B: AZD9833 monotherapy expansion.

  • AZD9833 with palbociclibDrug

    Part C: AZD9833 in combination with palbociclib dose escalation

  • AZD9833 with palbociclibDrug

    Part D: AZD9833 in combination with palbociclib expansion

  • AZD9833 with everolimusDrug

    Part E: AZD9833 in combination with everolimus dose escalation

  • AZD9833 with everolimusDrug

    Part F: AZD9833 in combination with everolimus dose expansion

  • AZD9833 with abemaciclibDrug

    Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation

  • AZD9833 with abemaciclibDrug

    Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion

  • AZD9833 with capivasertibDrug

    Part I: AZD9833 in combination with capivasertib dose escalation

  • AZD9833 with capivasertibDrug

    Part J: AZD9833 in combination with capivasertib dose expansion

  • AZD9833 with ribociclibDrug

    Part K: AZD9833 in combination with ribociclib (± anastrozole) dose escalation

  • AZD9833 with ribociclibDrug

    Part L: AZD9833 in combination with ribociclib (± anastrozole) dose expansion

  • AZD9833 with anastrozoleDrug

    Part M: AZD9833 in combination with anastrozole dose escalation

  • AZD9833 with anastrozoleDrug

    Part N: AZD9833 in combination with anastrozole dose expansion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects with dose-limiting toxicity, as defined in the protocol.Time frame: Minimum observation period 28 days on treatment.
  2. The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.Time frame: Minimum observation period 28 days on treatment, and will continue until the subject is off the study (approximately 1 year).

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Aurora, Colorado

  • Research Site

    Sarasota, Florida

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Nashville, Tennessee

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Barcelona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Valencia, Spain

  • Research Site

    Cambridge, United Kingdom

  • Research Site

    Leeds, United Kingdom

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Sutton, United Kingdom

  • Research Site

    Sutton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.